A new study has identified a novel strategy for treating acute myelogenous leukemia (AML), an aggressive blood cancer for which the median survival time following diagnosis remains just 8.5 months.

Scientists have discovered how aging blood stem cells acquire mutations that give them a growth edge, creating fertile ground for the development of clonol hematopoiesis, a condition that dramatically ...